Currently, after having demonstrated anti-tumor activity in pre-clinical and animal tumor models[8], several CXCR4 antagonists are being evaluated in clinical studies for treatment of patients with hematological and solid tumors[9]. Here, CXCR4 is linked to neoplasm.